Development of a broad-spectrum antiviral with activity against Ebola virus

M. Javad Aman, Michael S. Kinch, Kelly Warfield, Travis Warren, Abdul Yunus, Sven Enterlein, Eric Stavale, Peifang Wang, Shaojing Chang, Qingsong Tang, Kevin Porter, Michael Goldblatt, Sina Bavari

Research output: Contribution to journalArticlepeer-review

83 Scopus citations


We report herein the identification of a small molecule therapeutic, FGI-106, which displays potent and broad-spectrum inhibition of lethal viral hemorrhagic fevers pathogens, including Ebola, Rift Valley and Dengue Fever viruses, in cell-based assays. Using mouse models of Ebola virus, we further demonstrate that FGI-106 can protect animals from an otherwise lethal infection when used either in a prophylactic or therapeutic setting. A single treatment, administered 1 day after infection, is sufficient to protect animals from lethal Ebola virus challenge. Cell-based assays also identified inhibitory activity against divergent virus families, which supports a hypothesis that FGI-106 interferes with a common pathway utilized by different viruses. These findings suggest FGI-106 may provide an opportunity for targeting viral diseases.

Original languageEnglish
Pages (from-to)245-251
Number of pages7
JournalAntiviral Research
Issue number3
StatePublished - Sep 2009


  • Antiviral
  • Dengue Fever
  • Ebola virus


Dive into the research topics of 'Development of a broad-spectrum antiviral with activity against Ebola virus'. Together they form a unique fingerprint.

Cite this